The U.S. Food and Drug Administration approved on Tuesday the first drug under its new fast-track program designed to shorten ...

An announcement from Praxis Precision Medicines ( ($PRAX) ) is now available. On December 9, 2025, Praxis Precision Medicines ...

Wockhardt's shares jumped 19.3% to ₹1,473 following the US FDA's acceptance of its antibiotic drug Zaynich's New Drug ...

Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a ...

Disc Medicine Inc. (NASDAQ: IRON) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, ...

Drugmaker Wockhardt said that the United States Food and Drug Administration (US FDA) had accepted the New Drug Application ...

Wockhardt's share price surged 6.5% following FDA acceptance of its New Drug Application for Zaynich, marking a significant ...

Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis ...

Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, ...

Ocular Therapeutix surged to a new four-year high on Monday after rallying for four consecutive days, with investor sentiment ...

Abivax receives a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ...

The U.S. Food and Drug Administration approved an Investigational New Drug (IND) application using efficacy data solely from ...